Based on previous observations linking high glycolytic metabolic activity to drug resistance in CRC cells, we examined whether targeting the LINC01852/SRSF5/PKM2 axis can sensitize CRC cells to 5-FU and L-OHP (Fig. 6A). Here, SRSF5 is linked to colorectal carcinoma.